title: Clinical effect of treating secondary asthma attacks of children Mycoplasma pneumoniae with combined therapy of montelukast and azithromycin.
abstract: To discuss the clinical effects of treating secondary asthma attacks of children Mycoplasma pneumoniae with combined therapy of montelukast and azithromycin.
  
  
  
  96 children patients diagnosed with secondary asthma attacks of Mycoplasma pneumonia were enrolled in this study. They were randomly divided into two groups: the control group (n=49) and the observation group (n=47). Patients in the control group received combined therapy using azithromycin and bronchodilators or glucocorticoid, and patients in the observation group received a combined therapy of montelukast, azithromycin and bronchodilators or glucocorticoid. The lung function indexes, T lymphocyte subpopulation, cytokines levels, positive rate of lgG and lgM, asthma control rate and recurrence rate were compared between groups before and after treatment.
  
  
  
  The levels of V-T, t-PTEF/t-E, MTIF/MTEF and TEF25/PTEF in both groups increased after treatment, but we observed a more significant improvement in the observation group. The CD4+ and CD4+/CD8+ levels in both groups also increased after the intervention, while the level of CD8+ decreased. The IL-10, IL-17 and TGF-β levels decreased more intensely in the observation group.
  
  
  
  The positive rate of lgG and lgM in both groups decreased significantly after the intervention. In the observation group, the asthma control rate was higher while the recurrence rate was lower. Although montelukast had little effect on improving the immune function, it was certainly beneficial for controlling the symptoms of asthma and improving the prognosis.
  
  
  
  Using combined therapy of montelukast and azithromycin for treating the secondary asthma attacks of children mycoplasma pneumonia can relieve immunological and inflammatory reactions and improve the lung function.
authors.affiliation: Department of Respiratory Medicine, Xuzhou Children's Hospital, Xuzhou, Jiangsu, China. zhangchonglin3611@163.com.
authors.forename: L
authors.initials: L
authors.lastname: Gong
authors.forename: L
authors.initials: L
authors.lastname: Xu
authors.forename: M
authors.initials: M
authors.lastname: Diao
authors.forename: F
authors.initials: F
authors.lastname: Guo
authors.forename: F-F
authors.initials: FF
authors.lastname: Bian
authors.forename: J
authors.initials: J
authors.lastname: Min
authors.forename: R
authors.initials: R
authors.lastname: Liu
authors.forename: C-L
authors.initials: CL
authors.lastname: Zhang
mesh_terms: D000085:Acetates / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D017963:Azithromycin / Q000627:therapeutic use*; D002648:Child; D003521:Cyclopropanes; D006801:Humans; D009177:Mycoplasma pneumoniae; D011019:Pneumonia, Mycoplasma / Q000188:drug therapy*; D011804:Quinolines / Q000627:therapeutic use*; D013440:Sulfides
chemical_list: D000085:Acetates; D003521:Cyclopropanes; D011804:Quinolines; D013440:Sulfides; D017963:Azithromycin; C093875:montelukast